Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/III, Randomized, Double-Blind, Placebo-Controlled Study of Carboplatin Plus Etoposide With or Without Atezolizumab (Anti PD-L1 Antibody) in Patients With Untreated Extensive-Stage Small Cell Lung Cancer

Next Previous
X
Search
Trial Profile

A Phase I/III, Randomized, Double-Blind, Placebo-Controlled Study of Carboplatin Plus Etoposide With or Without Atezolizumab (Anti PD-L1 Antibody) in Patients With Untreated Extensive-Stage Small Cell Lung Cancer

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 06 Feb 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Atezolizumab (Primary) ; Carboplatin; Etoposide
  • Indications Small cell lung cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms IMpower133
  • Sponsors Chugai Pharmaceutical; Genentech; Roche

    • Most Recent Events

    • 01 Dec 2023 Results of exploratory analysis on patient and tumor characteristics associated with long-term survival in this study, as well as data from gene expression analyses in long-term survivors, published in the Lung Cancer.
    • 30 Nov 2022 Status changed from active, no longer recruiting to completed.
    • 27 Jul 2022 This trial has been completed in Hungary (Date of the global end of the trial : 07-Jul-2022), according to European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top